Schwarz Caroline, Schubert Raphael, Schwarz Michael, Schütz Angelika, Jenke Anika, Bauer David, Steinwender Benjamin, Gutic Enisa, Reiberger Thomas, Haltmayer Hans, Gschwantler Michael
Klinik Ottakring, Department of Internal Medicine IV, Vienna, Austria.
Medical University of Vienna, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Vienna, Austria.
J Virus Erad. 2023 Jul 27;9(3):100338. doi: 10.1016/j.jve.2023.100338. eCollection 2023 Sep.
Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid agonist therapy (OAT).
OAT prescriptions were required monthly at one of nine approved authorities, making them ideal platforms for hepatitis C virus (HCV) screening. All PWIDs attending these authorities between January 2019 and March 2020 were offered on-site HCV screening, and consecutive HCV RNA PCR in case of positive HCV serology. In HCV viremic PWIDs, offsite referral to HCV care and treatment according to directly observed therapy (DOT) alongside OAT were performed.
4,327/6,665 (64.9%) individuals were contacted before the COVID-19-related project discontinuation. There were 1,538/4,327 (35.5%) individuals who had participated in the study. HCV serology was available in 1,510/1,538 (98.2%): 795/1,519 (52.6%) had a positive serology, among whom 632 (79.5%) were followed-up with a PCR test. In 8/1,538 (0.5%) additional study participants HCV RNA PCR was assessed without prior serological screening. 239/640 (37.3%) individuals were HCV viremic with 51 (21.3%) having started on direct-acting antivirals (DAAs). 48/51 (94.1%) had completed treatment, among whom 42 (87.5% according to ITT) had achieved sustained virologic response at 12 weeks after completing treatment (SVR12) and 6 (12.5%) had been lost to follow-up after completion of therapy (SVR12 according to mITT: 42/42, 100%). No treatment failures had occurred.
Providing integrated point-of-care HCV screening/diagnostic testing at central OAT approved centers, followed by DOT with DAAs, represents an effective HCV microelimination strategy. While some PWIDs were lost in the cascade to cure and the absolute number of SVR was limited by the COVID-19 pandemic, our approach will allow linkage to care in a large proportion of Viennese PWIDs.
丙型肝炎在注射毒品者(PWIDs)中仍然高度流行。我们提出了一种针对6665名登记接受阿片类激动剂治疗(OAT)的维也纳PWIDs进行筛查/诊断检测及治疗的综合方法。
在九个获批机构之一每月开具OAT处方,这使其成为丙型肝炎病毒(HCV)筛查的理想平台。2019年1月至2020年3月期间到这些机构就诊的所有PWIDs均接受现场HCV筛查,HCV血清学检测呈阳性者进行连续HCV RNA聚合酶链反应检测。对于HCV病毒血症的PWIDs,除OAT外,还根据直接观察治疗(DOT)将其转诊至HCV护理和治疗机构。
在与COVID-19相关的项目终止前,联系了4327/6665(64.9%)的个体。有1538/4327(35.5%)的个体参与了该研究。1510/1538(98.2%)的个体有HCV血清学检测结果:795/1519(52.6%)血清学检测呈阳性,其中632例(79.5%)接受了PCR检测随访。在8/1538(0.5%)的其他研究参与者中,未进行血清学筛查直接进行了HCV RNA PCR检测。239/640(37.3%)的个体为HCV病毒血症,其中51例(21.3%)开始使用直接抗病毒药物(DAAs)。48/51(94.1%)完成了治疗,其中42例(根据意向性分析为87.5%)在完成治疗后12周达到持续病毒学应答(SVR12),6例(12.5%)在治疗完成后失访(根据改良意向性分析的SVR12:42/42,100%)。未发生治疗失败。
在OAT获批的中心提供综合的即时HCV筛查/诊断检测,随后采用DOT联合DAAs治疗,是一种有效的HCV微消除策略。虽然在治愈过程中有一些PWIDs失访,且SVR的绝对数量受COVID-19大流行限制,但我们的方法将使很大一部分维也纳PWIDs能够获得护理。